Key facts: CMS sets 2027 TearCare code at $1,000; target rises to $11
Sight Sciences (SGHT) reported that CMS set the 2027 fee for TearCare SmartLids at $1,000, effective January 1. The company's average 12-month price target increased to $11, suggesting 14% upside from its recent close. Analysts maintain a Buy consensus.
How this was made
The 30-second read
Why it matters
The $1,000 code could boost Sight Sciences' revenue if claims are approved, but actual payment is not assured.
Market read
A modest regulatory update with potential upside for a niche medical device maker.
What to watch
Potential delays in provider adoption and competition from alternative treatments.
Background
CMS periodically updates its fee schedule, affecting Medicare reimbursement for medical devices.
Ticker impact
CMS set a new supply code for Sight Sciences' TearCare device at $1,000, prompting analysts to raise the price target.
potential upside pressure as investors price in higher reimbursement expectations
Reimbursement code changes are a direct catalyst for revenue growth in medical device firms.
Market effects
May signal broader CMS reimbursement updates for similar ophthalmic devices.
Limited to U.S. Medicare reimbursement landscape.
Low, as the code applies to U.S. Medicare only.
Counterpoint
The code does not guarantee payment, so the upside may be overstated.
Key entities
- CompanySight Sciences
Developer of TearCare SmartLids, a dry eye treatment device.
- Regulatory AgencyCMS
U.S. Centers for Medicare & Medicaid Services, sets Medicare fee schedules.
